Follow The Filings

BFRI Biofrontera

Biofrontera earnings company data as of 4:48 AM ET 10/23

  • 0 of 1 EPS beats

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS -0.04 -0.05 Miss
Rev — $4.5M —

Insider trades

Open-market buys and sales by BFRI's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BFRI insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 4 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
10-K/A
8-K 5.07
8-K 2.02,9.01
10-Q
DEF 14A
8-K 2.02,9.01
10-K
8-K 7.01,9.01
8-K 8.01,9.01
SCHEDULE 13G/A —
8-K 7.01,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
8-K 3.01
S-1
8-K 2.02,9.01
SCHEDULE 13G/A —
10-Q
8-K 8.01
8-K 1.01,2.01,7.01,9.01
8-K 1.01,2.01,3.02,8.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.